Insights
Search Results
Client Highlights
1.13.26
Wilson Sonsini Advises Proxima on $80 Million Seed Financing
On January 13, 2026, Proxima (formerly VantAI), the AI-native biotech company pioneering the next generation of AI-driven drug discovery for proximity therapeutics, announced an oversubscribed $80 million Seed financing.
Client Highlights
10.01.25
Firm Advises Predicta Biosciences on IP Matters Related to Oversubscribed $23.4 Million Series A
On October 1, 2025, Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, announced it has raised an oversubscribed $23.4 million Series A financing led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute, and Myeloma Solutions Fund. Wilson Sonsini Goodrich & Rosati advised Predicta on IP matters related to the transaction.
News Articles
10.01.25
LMG Life Sciences Recognizes Wilson Sonsini, Attorneys in 2025 Guide
On September 30, 2025, LMG Life Sciences announced the 2025 edition of its guide, which identifies and ranks the leading law firms and individuals in the life sciences industry across the United States. The rankings are the result of firm participation in questionnaires, partner interviews to gather market feedback, client surveys, and independent research. LMG Life Sciences has conducted research and published rankings since 2012. This year, six Wilson Sonsini practices and 18 attorneys have been recognized in the guide.
News Articles
8.28.25
Mark Bellomy Honored as 2025 “Unsung Hero” for New England Law Awards
On August 20, 2025, Wilson Sonsini technology transactions partner Mark Bellomy was named among three honorees in the “Unsung Hero” category of Law.com’s 2025 New England Legal Awards, which honor attorneys and firms from Connecticut, Maine, Vermont, New Hampshire, Massachusetts, and Rhode Island. Honorees will be recognized at an awards dinner on October 23 in Boston.
Client Highlights
12.19.24
Wilson Sonsini Advises TigaTx on $35.5 Million in ARPA-H and NIH Funding for Engineered IgA Platform for Cancer and Infectious Disease
On December 19, 2024, Boston-based biotech company TigaTx announced it had received up to $33.5 million in funding from the Advanced Research Projects Agency for Health (ARPA-H) and an additional $2 million, two-year, direct-to-phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI). Wilson Sonsini Goodrich & Rosati advised TigaTx on the transaction.
News Articles
9.17.24
Wilson Sonsini, Attorneys Recognized in 2024 Edition of LMG Life Sciences
On September 17, 2024, LMG Life Sciences recognized several Wilson Sonsini practices and 19 of its attorneys in the 2024 edition of its guide, which identifies and ranks the leading law firms and individuals in the life sciences industry across the United States. The rankings are the result firm participation in questionnaires, partner interviews to gather market feedback, client surveys, and independent research. LMG Life Sciences has conducted research and published rankings since 2012.
Client Highlights
7.11.24
Wilson Sonsini Advises Fluent BioSciences on Acquisition by Illumina
On July 9, 2024, Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced that it has acquired Fluent BioSciences (Fluent), developer of an emerging and highly differentiated single-cell technology. Wilson Sonsini Goodrich & Rosati advised Fluent on the transaction.
Client Highlights
6.10.24
Firm Advises Marengo Therapeutics on Expansion of Research Partnership with Ipsen
On June 7, 2024, global biopharmaceutical company Ipsen and clinical-stage biotech company Marengo Therapeutics announced the expansion of their ongoing oncology research partnership to include TriSTAR, Marengo’s next-generation, precision T cell engager (TCE) technology. Wilson Sonsini Goodrich & Rosati advised Marengo Therapeutics on the transaction.
Traditional TCEs targeting “cold” tumors have limited efficacy due to poor T cell quality and exhaustion. Marengo’s proprietary first-in-class TriSTAR TCEs have the potential to overcome these limitations, redirecting a new and expanded pool of highly activated memory Vβ T cells to the tumor. The teams will focus on exploring potential in cold tumors, which typically fail to trigger a strong immune response when treated with TCEs.
Under the terms of the agreement, Ipsen will assume responsibility for all activities following development candidate nomination. Marengo will receive an upfront payment and potential payments up to a total of $1.2 billion if all milestones are met, in addition to tiered sales royalty payments.
The Wilson Sonsini team advising Marengo Therapeutics on the transaction included Mark Bellomy, Chris McAndrew, Lauren Wardle, and Angel Wang.
Traditional TCEs targeting “cold” tumors have limited efficacy due to poor T cell quality and exhaustion. Marengo’s proprietary first-in-class TriSTAR TCEs have the potential to overcome these limitations, redirecting a new and expanded pool of highly activated memory Vβ T cells to the tumor. The teams will focus on exploring potential in cold tumors, which typically fail to trigger a strong immune response when treated with TCEs.
Under the terms of the agreement, Ipsen will assume responsibility for all activities following development candidate nomination. Marengo will receive an upfront payment and potential payments up to a total of $1.2 billion if all milestones are met, in addition to tiered sales royalty payments.
The Wilson Sonsini team advising Marengo Therapeutics on the transaction included Mark Bellomy, Chris McAndrew, Lauren Wardle, and Angel Wang.
Client Highlights
1.12.24
Firm Advises JIXING on Acquisition of BIIB131 from Biogen
On January 11, 2024, Ji Xing Pharmaceuticals (JIXING), a clinical-stage biopharmaceutical company committed to bringing innovative medicines to underserved patients with serious and life-threatening diseases, announced the acquisition of BIIB131 from Biogen for clinical development. Wilson Sonsini Goodrich & Rosati advised JIXING on the transaction.
BIIB131 is an investigational drug for acute ischemic stroke (AIS). Its proposed mechanism of action includes both thrombolytic and anti-inflammatory activities. By restoring critical blood flow following acute stroke, it may benefit more patients over current standard of care by extending the otherwise short treatment window.
BIIB131 is an investigational drug for acute ischemic stroke (AIS). Its proposed mechanism of action includes both thrombolytic and anti-inflammatory activities. By restoring critical blood flow following acute stroke, it may benefit more patients over current standard of care by extending the otherwise short treatment window.
Client Highlights
1.12.24
Wilson Sonsini Advises JIXING on Strategic Collaborations with TMS
On January 11, 2024, TMS Co., Ltd. (TMS) and Ji Xing Pharmaceuticals Limited (JIXING) announced that they have entered into a strategic partnership established subsequent to the assignment of an option agreement from Biogen MA Inc. (Biogen) to JIXING, originally between TMS and Biogen, followed by an amendment immediately in effect upon the assignment. Wilson Sonsini Goodrich & Rosati advised JIXING on the transaction.
TMS and JIXING will form a collaborative partnership to globally develop TMS-007—a novel antithrombotic agent developed for the treatment of acute ischemic stroke (AIS)—with TMS regaining royalty-free Japan rights while JIXING will lead the development and commercialization of TMS-007 in the rest of the world. TMS and JIXING will join forces to expeditiously develop and launch TMS-007 globally, facilitated by the formation of a Joint Development Committee. In addition, TMS will receive an upfront payment of $5 million in the form of JIXING equity, up to $12.5 million in development milestones, up to $355 million in commercial milestones, and tiered royalties consistent with the original Option Agreement.
Concurrently, JIXING licenses to TMS exclusive Japan rights of JX09. JX09 is an oral, novel, small molecule ASI in development for the treatment of resistant and/or uncontrolled hypertension by JIXING, which is planned to enter into a first-in-human Phase 1 clinical trial in early 2024.
The Wilson Sonsini team that advised JIXING on the transactions included partners Michael Hostetler, Farah Gerdes, Mark Bellomy, Greg Broome, and Jen Fang; associates Zack Burns, TJ Tingjie Li, Ying Chen, Brandon King, Christina Fuleihan, Hee Min Noh, and Zamin Raza; and patent agent Jamie Gleason-Bremer.
For more information, please see the companies’ news release.
TMS and JIXING will form a collaborative partnership to globally develop TMS-007—a novel antithrombotic agent developed for the treatment of acute ischemic stroke (AIS)—with TMS regaining royalty-free Japan rights while JIXING will lead the development and commercialization of TMS-007 in the rest of the world. TMS and JIXING will join forces to expeditiously develop and launch TMS-007 globally, facilitated by the formation of a Joint Development Committee. In addition, TMS will receive an upfront payment of $5 million in the form of JIXING equity, up to $12.5 million in development milestones, up to $355 million in commercial milestones, and tiered royalties consistent with the original Option Agreement.
Concurrently, JIXING licenses to TMS exclusive Japan rights of JX09. JX09 is an oral, novel, small molecule ASI in development for the treatment of resistant and/or uncontrolled hypertension by JIXING, which is planned to enter into a first-in-human Phase 1 clinical trial in early 2024.
The Wilson Sonsini team that advised JIXING on the transactions included partners Michael Hostetler, Farah Gerdes, Mark Bellomy, Greg Broome, and Jen Fang; associates Zack Burns, TJ Tingjie Li, Ying Chen, Brandon King, Christina Fuleihan, Hee Min Noh, and Zamin Raza; and patent agent Jamie Gleason-Bremer.
For more information, please see the companies’ news release.
News Articles
10.05.22
Wilson Sonsini and Attorneys Recognized in 2022 Edition of LMG Life Sciences
LMG Life Sciences recognized several Wilson Sonsini practices and 16 of its attorneys in the 2022 edition of its guide, which identifies and ranks the leading law firms and individuals in the life sciences industry.